Navigation Links
Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
Date:10/9/2007

LYON, France, Oct. 9 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that data from a study in mice demonstrated the potential of its patented Vaxfectin(TM) adjuvant to be used as a dose-sparing agent with a protein-based H5N1 pandemic influenza vaccine currently stockpiled by the U.S. government. Dose-sparing ability could be critical in extending limited vaccine supplies to protect the greatest number of people in the event of a pandemic influenza outbreak. Alain Rolland, Pharm.D., Ph.D., Vical's Senior Vice President of Product Development, presented the data at the World Vaccine Congress (Lyon, France, October 8 - 10).

Vaxfectin(TM)-formulated Measles DNA Vaccine

The company also announced that a measles DNA vaccine formulated with the company's Vaxfectin(TM) adjuvant elicited sustained protective levels of neutralizing antibodies in infant (6 - 10 week old) nonhuman primates confirmed by complete protection following challenge one year after intradermal vaccination, with no clinical signs of disease and no culturable virus after challenge. In May, the company announced similar results in juvenile (1 - 2 year old) nonhuman primates. Both measles studies were conducted in collaboration with Diane E. Griffin, M.D., Ph.D., Alfred and Jill Sommer Professor and Chair of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, under a grant from the Bill and Melinda Gates Foundation.

"We continue to expand the database demonstrating the dose-sparing and immunogenicity-enhancing capabilities of our Vaxfectin(TM) adjuvant," said Dr. Rolland, "as well as its potential safety and tolerability advantages. Our lead DNA vaccine candidate against H5N1
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)..., Nov. 25 Poniard,Pharm...tical company focused on,innovative oncology ther...strategic alternatives for its preclinical researc... its resources on the clinical development of pico...t the initial commercialization of,picoplatin in ...
(Date:11/25/2008)...ire-FirstCall/ -- CardioVascular,BioTherapeutics,...that it has,dosed the first patient in North Amer...rial to treat patients with severe coronary heart ...t of CORonary heart Disease) trial will include,f...oses in approximately 120,patients with severe co...
(Date:11/24/2008)...PRNewswire-FirstCall/ -- Leaders of Schering-Ploug...ate for investors on the company,s research pipeli...hat includes 46 new entities in clinical trials or...dies. , , "Research and development is addi...ontinue our transformation," said Fred Hassan, cha...
(Date:11/24/2008)...day Unveils Rich Development Pipeline of Compounds...ORTH, N.J., Nov. 24 Sche...led top-line results of a long-term Phase III clin...S(TM) (asenapine) demonstrating efficacy and safet... trial, asenapine was statistically significantly ...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 2Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 3Hear Indiana Announces Talk Walk Run 2008 18272 1Hear Indiana Announces Talk Walk Run 2008 18272 2Hear Indiana Announces Talk Walk Run 2008 18272 3Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 1Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 1Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 3GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 1GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 2GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 3
... /PRNewswire/ -- Results of the,Option (TOcilizuma...ers) trial, the first multinational Phase III stud...ith Actemra (either 4mg/kg,or 8mg/kg) plus methotr...ant improvement in the signs and symptoms of moder...o patients treated with,placebo and methotrexate, ...
...Biotech (OMX Nordic: ACTI) presented,pre-clinical ...The,European League Against Rheumatism, <a target=...rg ) conference, June,13-16*. , "The new pre-clin...nt inhibitory effect on disease development in an,... commented Sven,Andréasson, President &...
Other Medicine Technology:Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2
(Date:12/2/2008)... Orion Health announces that the Sou...of Juneau, Alaska, has selected the Rhapsody&trade...nic health record, radiology, pharmacy, laboratory.... It also plans to extend connectivity to statewid...unization registry) and AKAIMS (an MIS and clinica...
(Date:12/2/2008)... Dec. 2 Population Serv...hensive project that could dramatically reduce the...malaria. The program will provide free artemisinin...community health workers to poor children suspecte...to treatment will be monitored to determine if it ...
(Date:12/1/2008)...es ,Asthma & Allergy Friendly, Toy Puppies to ... Much has been made of P...ily dog. But concerns about his daughter,s asthma...ew first-dad from making a decision. So, in the m...ica (AAFA) is donating 2 "asthma & allergy fri...
(Date:12/1/2008)...New research reveals that computed tomography (CT)...has the potential to screen for two diseases at on...h commonly affect adults over age 50. Results of t...ting of the Radiological Society of North America ...screening for colorectal cancer, we were able to i...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...id could provide ample energy if used properly is ...rican Journal of Physiology - Endocrinology and Me...d colleagues Takeshi Hashimoto and Rajaa Hussien i...ratory add one of the last puzzle pieces to the la...
... to a report published in Geneva it was found that...research work on diseases such as AIDS and malaria... many developing countries, especially in sub-Saha...y the Global Forum for Health Research. Stephen Ma...
...cefully can sometimes be a problem especially when... facilities looms large. //Marilyn Rantz, nursing ... calls this as a slippery slope and says that ther...m getting onto this slope. Consumers say they nev...
...more number of bus drivers and conductors in India...is that of the bus conductor Ravindra Kamble (34).... conductors in the last one year have been tested ...programme was started by General Manager SS Kshatr...
Other Medicine News:Health News:Lactic acid a potent energy giver if used properly! 2
Inquiry H Steerable Catheter. Steerable atrial mapping catheter offers a variety of designs and a unique 45 offset for catheter stability. 10 to 24 electrodes, regular and large steerable curves, ina
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures.
...or a complete line of deflectable coronary sinus (...all with the quality, reliability and precise perf...atheter technology. All of our deflectable coronar...gned and constructed to help minimize the frustrat...
Inquiry 5FR Soft HIS diagnostic catheters provide the electrophysiologist with a uniquely designed curve that allows for placement and recording in the HIS bundle. In addition, the soft tubing is des
Medicine Products: